Fc-IgG Anti-VEGF Fusion Proteins for Longer Ocular Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-VEGF agents used for treating ocular neovascular disorders require frequent intravitreal injections due to short half-life, which can lead to poor patient compliance and suboptimal therapeutic outcomes.
Innovation Solution
Development of an anti-VEGF agent in the form of an Fc-IgG construct that incorporates specific VEGF binding domains of VEGFR-1, such as IgG-like domains 2 and 3, with strong heparin-binding characteristics to enhance pharmacokinetics and prolong half-life after intravitreal administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current anti-VEGF agents are used for treating ocular neovascular disorders, then the therapeutic effect is achieved, but the frequency of injections must be high due to short half-life
Solution Approach 1:
The patent applies composite materials by creating a fusion protein that combines the VEGF-binding domain of VEGFR-1 (which provides therapeutic function) with the Fc region of IgG (which provides extended half-life through reduced renal clearance and potential FcRn recycling). This composite structure achieves both prolonged duration of action and reduced injection frequency, resolving the technical contradiction between half-life and productivity.
2Reliability
If frequent intravitreal injections are administered, then therapeutic efficacy is maintained, but patient compliance deteriorates
Solution Approach 1:
The patent applies dynamics by engineering the anti-VEGF agent with modifiable pharmacokinetic properties through structural modification (fusion with Fc region). This creates a dynamic system where the drug's half-life can be extended without compromising therapeutic efficacy, thereby reducing injection frequency and improving patient compliance while maintaining reliability of treatment outcomes.
3Productivity
If the anti-VEGF agent structure is modified to prolong half-life, then injection frequency is reduced, but the complexity of the agent increases
Solution Approach 1:
The patent applies universality by designing a fusion protein where the Fc region serves multiple functions: (1) reducing renal clearance to extend half-life, (2) providing a platform for potential further modifications, and (3) maintaining immunogenic safety. This multi-functional design achieves reduced injection frequency without excessive structural complexity, as the Fc region is a well-characterized, standardized protein domain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new anti-VEGF agent achieves prolonged efficacy by reducing the frequency of injections, effectively inhibiting angiogenesis and treating conditions like age-related macular degeneration and other ocular diseases with improved therapeutic outcomes.
Implementation Method 1
VEGF binds both VEGFR-1 and VEGFR-2. A third member of this family of RTKs, VEGFR-3, binds VEGF-C and VEGF-D
Implementation Method 2
incorporates specific VEGF binding domains of VEGFR-1, such as IgG-like domains 2 and 3, with strong heparin-binding characteristics to enhance pharmacokinetics and prolong half-life
Data Source
AI summary
Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.